Evopoint Biosciences Co., Ltd. (SHA:688837)
China · Delayed Price · Currency is CNY 49.40
+5.79 (13.28%)
Sep 30, 2026, 3:00 PM CST
Evopoint Biosciences Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Cash & Equivalents | 849.76 | 761.04 | 300.27 | 230.46 | 117.76 |
Short-Term Investments | - | - | - | - | 28.52 |
Trading Asset Securities | 133.6 | 57.36 | 83.16 | 300.01 | 283.09 |
Cash & Short-Term Investments | 983.36 | 818.39 | 383.42 | 530.47 | 429.37 |
Cash Growth | - | 113.44% | -27.72% | 23.55% | - |
Other Receivables | 2.06 | 2.18 | 1.43 | 10.97 | 1.22 |
Receivables | 2.06 | 2.18 | 1.43 | 10.97 | 1.22 |
Other Current Assets | 108.16 | 90.98 | 41.85 | 22.08 | 16.54 |
Total Current Assets | 1,094 | 911.55 | 426.71 | 563.52 | 447.13 |
Property, Plant & Equipment | 442.86 | 429.4 | 434.28 | 411.29 | 301.57 |
Long-Term Investments | 358.06 | 334.32 | 178.48 | 124.6 | 113.82 |
Other Intangible Assets | 8.25 | 8.86 | 9.01 | 8.96 | 8.92 |
Long-Term Deferred Charges | 0.24 | 0.29 | 4.19 | 8.67 | 14.07 |
Other Long-Term Assets | 76.29 | 58.36 | 35.61 | 19.53 | 30.62 |
Total Assets | 1,979 | 1,743 | 1,088 | 1,137 | 916.13 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Accounts Payable | 118.13 | 97.22 | 97.36 | 52.03 | 49.77 |
Accrued Expenses | 14.53 | 21.32 | 28.98 | 25.56 | 18.43 |
Short-Term Debt | - | 0.7 | - | 30.02 | 55.05 |
Current Portion of Long-Term Debt | 401.46 | 159.67 | 116.49 | 28.14 | 9.13 |
Current Portion of Leases | - | 10.01 | 7.34 | 8.61 | 10.8 |
Other Current Liabilities | 11.99 | 19.99 | 60.31 | 58.57 | 27.91 |
Total Current Liabilities | 548.14 | 308.91 | 310.47 | 202.93 | 171.09 |
Long-Term Debt | 881.45 | 713.86 | 397.65 | 338.7 | 268.46 |
Long-Term Leases | 11.28 | 14.01 | - | 6.75 | 17.23 |
Long-Term Unearned Revenue | 2.81 | 2.98 | 20.7 | 9.15 | - |
Total Liabilities | 1,444 | 1,040 | 728.82 | 557.54 | 456.78 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Common Stock | 370.17 | 370.17 | 370.17 | 360 | 52.73 |
Additional Paid-In Capital | 1,782 | 1,782 | 1,641 | 1,484 | 1,245 |
Retained Earnings | -1,617 | -1,449 | -1,652 | -1,266 | -838.95 |
Comprehensive Income & Other | -0.01 | 0.53 | 0.25 | 0.89 | 0.39 |
Shareholders' Equity | 535.59 | 703.03 | 359.46 | 579.02 | 459.35 |
Total Liabilities & Equity | 1,979 | 1,743 | 1,088 | 1,137 | 916.13 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Total Debt | 1,294 | 898.25 | 521.48 | 412.22 | 360.67 |
Net Cash (Debt) | -310.83 | -79.86 | -138.05 | 118.24 | 68.7 |
Net Cash Growth | - | - | - | 72.11% | - |
Net Cash Per Share | -0.84 | -0.22 | -0.38 | 0.35 | 0.21 |
Filing Date Shares Outstanding | 372.85 | 370.17 | 370.17 | 341.51 | 325.8 |
Total Common Shares Outstanding | 372.85 | 370.17 | 370.17 | 341.51 | 325.8 |
Working Capital | 545.43 | 602.64 | 116.24 | 360.59 | 276.04 |
Book Value Per Share | 1.44 | 1.90 | 0.97 | 1.70 | 1.41 |
Tangible Book Value | 527.34 | 694.17 | 350.45 | 570.06 | 450.43 |
Tangible Book Value Per Share | 1.41 | 1.88 | 0.95 | 1.67 | 1.38 |
Buildings | - | 265.41 | - | - | - |
Machinery | - | 206.24 | - | - | - |
Construction In Progress | - | 2.31 | - | - | - |